Chemical Structure (Pradaxa 01)
Pradaxa Pellet
Product Images NDC 0597-0425
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Pradaxa (NDC 0597-0425). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Pradaxa 02)
Not available.*
Figure 2 (Pradaxa 03)
This appears to be a medication list with dosages for different drugs such as Atorvastatin, Clopidogrel and Ranitidine. The list also includes the frequency of intake and abbreviations such as "mg" and "qd" which may refer to specific instructions or dosages. It is unclear what the last section with "Fold Change and 90% CT" is referring to.*
Figure (Pradaxa 04)
Figure (Pradaxa 05)
Figure (Pradaxa 06)
Figure (Pradaxa 07)
Figure (Pradaxa 08)
Figure (Pradaxa 09)
Figure (Pradaxa 10)
Figure (Pradaxa 11)
Figure (Pradaxa 12)
Figure (Pradaxa 13)
Figure (Pradaxa 14)
Figure (Pradaxa 15)
Figure (Pradaxa 16)
Figure (Pradaxa 17)
Principal Display Panel (20 mg Packet Bag Carton)
The text provides information about Pradaxa oral pellets, a medication with the active ingredient dabigatran etexilate in 20 mg dose packets. It is advised not to open the packets until ready to use and unused pellets should be discarded 6 months after opening the aluminum bag. The medication should be dispensed in a specific container and cannot be substituted with other dabigatran etexilate forms. The information includes the manufacturer's name and product details.*
Principal Display Panel (30 mg Packet Bag Carton)
This is a product description for Pradaxa oral pellets, a medication containing dabigatran etexilate, dispensed in a unit of use container. The medication guide enclosed provides information on how to use Pradaxa. Each packet contains 30mg of the medication and is not interchangeable with other dosages of dabigatran etexilate. The aluminum bag contains 60 packets and should not be opened until the user is ready to use them. Unused pellets should be discarded after 6 months. The manufacturer is Boehringer Ingelheim.*
Principal Display Panel (40 mg Packet Bag Carton)
This is a description of Pradaxa, a medication used to prevent blood clots in adults who have certain conditions, such as atrial fibrillation. The medication is in the form of oral pellets, containing 40mg per packet. The packaging has a warning not to open the packets until use, and to discard any unused medication after 6 months of opening the aluminum bag. The text also includes the NDC number, caution against substituting with other forms of dabigatran etexilate, and the name of the manufacturer, Boehringer Ingelheim.*
Principal Display Panel (50 mg Packet Bag Carton)
This is a description of Pradaxa, an oral pellet medication containing dabigatran etexilate, which is dispensed in a unit of use container with each packet containing 50 mg. It is essential not to open the packets until usage and discard any unused pellets after six months of opening the aluminum bag. The medication is not interchangeable on a milligram-to-milligram basis with other forms of dabigatran etexilate dosage. The package contains one aluminum bag with 60 packets. There is no other available information in the text.*
Principal Display Panel (110 mg Packet Bag Carton)
NDC 0597-0445-87 is a unit of use container for Pradaxa oral pellets, which should not be substituted on a mg-to-mg basis with other dabigatran etexilate dosage forms. It is important to discard unused PRADAXA oral pellets 6 months after opening the aluminum bag. The product is manufactured by Boehringer.*
Principal Display Panel (150 mg Packet Bag Carton)
This is a description of Pradaxa, an oral medication used to prevent blood clots. It comes in packets containing 150mg of dabigatran etexilate, and should not be substituted with other dosage forms. The packets should not be opened until use, and any unused medication should be discarded six months after opening the aluminum bag. The medication is dispensed in a unit of use container with NDC 0597-0450-16.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
